Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 10/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7297189 | 0.78 | EPHX1 (0.57) | CYP3A4CYP1A2KDM4EHCRTR1KMT2A | |
| SCHEMBL4131412 | 0.77 | KDM4E (0.60) | MLNRCYP3A4CYP2D6KDM4EKCNH2 | |
| SCHEMBL16598608 | 0.72 | KMT2A (0.57) | KMT2A | |
| SCHEMBL14633046 | 0.72 | MLNR (0.74) | MLNRCYP3A4CYP2D6CYP1A2GHSR | |
| SCHEMBL4752136 | 0.72 | MLNR (0.67) | MLNRCYP3A4CYP2D6CYP1A2GHSR | |
| SCHEMBL377914 | 0.70 | ALDH1A1 (0.62) | MLNRCYP3A4CYP2D6KDM4EKCNH2 | |
| SCHEMBL16812295 | 0.70 | APOBEC3A (0.48) | — | |
| SCHEMBL17275249 | 0.70 | HTR2B (0.56) | KDM4E | |
| SCHEMBL1803049 | 0.69 | KDM4E (0.66) | KDM4EKMT2A | |
| SCHEMBL13844240 | 0.69 | KDM4E (0.71) | MLNRCYP3A4CYP2D6KDM4EKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GLAXO GROUP LIMITED | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GPR68, GPR55, GPR88 | MLNR 207/4885CYP3A4 784/4885CYP2D6 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.